The Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19

Helixmith Co., Ltd.

Overview

This study will assess the safety and efficacy and tolerability of TADIOS compared to placebo in patients with mild to moderate COVID-19.

100 patients diagnosed with COVID-19 by RT-PCR were randomized in a ratio of 1:1 into TADIOS group and placebo group to evaluate efficacy and safety after intake over 10 days.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

QUADRUPLE

Conditions

COVID-19

Interventions

TADIOSDRUG

TADIOS is a combination extract which composed of three herbs, and each herbal medicine has been traditionally used as a food or a herbal medicine treating various respiratory diseases in Asia

PlaceboDRUG

Combination of the following Lactose hydrate, Microcrystalline cellulose, Colloidal silicone dioxide, Povidone, Croscarmellose sodium, Magnesium stearate, Tabshield(79O245)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or Female, aged between 18 to 65 years (both inclusive) 2. Confirmed Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first infection by a reverse transcription polymerase chain reaction (RT-PCR) assay in nasal swab or oropharyngeal swab samples. 3. Patients who are hospitalized into designated hospital for COVID-19 treatment 4. Patients who can be treated within 24 hours after confirmed diagnosis with COVID-19 5. Patients with mild COVID-19 or moderate COVID-19 according to clinical management guideline of Government of India. * Mild Illness: Patients with uncomplicated upper respiratory tract viral infection, may have non-specific symptoms such as fever, cough, sore throat, nasal congestion, malaise, and headache. The elderly may present with atypical symptoms. These patients do not have any signs of dehydration, sepsis or shortness of breath. * Moderate Illness: Patient with pneumonia and no signs of severe pneumonia (Chest X-ray will be performed to rule out pneumonia in the suspected subjects). 6. Patients who have signed the written informed consent form approved by Ethics Committee to participate after understanding explanations regarding the study 7. Those who can comply with the requirements and processes in the clinical study 8. Women of childbearing age must be negative to urine pregnancy test during screening Exclusion Criteria: 1. Patients with severe COVID-19 2. Self-reported history of meaningful circulatory, renal, gastrointestinal, liver, endocrinal, hematological, or mental disease, or other serious diseases or alcohol or drug addiction that may cause safety issues or confusion in the interpretation of clinical research results by the principal investigator's judgment 3. Female patients who are pregnant (confirmed through urine pregnancy test) or breastfeeding 4. Patients with cardiovascular, liver, cancer and kidney disease. 5. Self-reported patients being a recipient of immunosuppressive therapy 6. Self-reported patients who are allergic to this dietary supplements 7. Patients taking a health functional food or medicine that may affect the body's antioxidant, anti-inflammatory activity, and lungs within 6 weeks of the first visit 8. Patients who participated in another clinical trial within 1 month before screening 9. Patients have any condition that in the judgement of investigator make the subject inappropriate for entry into this study 10. Patients consuming any herbal medicine 11. Self-reported patients with cases of surgical menopause (hysterectomy, oophorectomy of both ovaries) or sterilization procedures (tubal ligation or tubectomy of both fallopian tubes). Menopause refers to 1 year of no menstruation.

Locations (6)

Vagus Super Specialty Hospital

Bangalore, Karnataka, India

Sparsh Superspeciality Hospital

Bangalore, Karnataka, India

Lakshmi Nursing Home

Kochi, Kerala, India

Chaitanya Hospital

Paravūr, Kerala, India

Outcomes

Primary Outcomes

Evaluation of antioxidative and inflammatory Biomarkers

Change from baseline in Antioxidative and inflamatory biomarkers: TNF-α, CRP, IL-6, IL-1ra, Hb, and ferritin.

Time frame: Day 1, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration

Clinical measurements - Ordinal Scale for COVID-19 Assessment

Change from baseline in Covid-19 8-point Ordinal Scale: 0 = Uninfected, 1 = Ambulatory without limitation of activity, 2 = Ambulatory with limitation of activity, 3 = Hospitalized mild disease, no oxygen, 4 = Hospitalized mild disease, supplemental oxygen, 5 = Hospitalized severe disease, non-invasive ventilation or high-flow oxygen, 6 = Hospitalized severe disease, intubation and mechanical ventilation, 7 = Hospitalized severe disease, ventilation plus additional organ support, 8 = Death.

Time frame: Day 1, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration

Clinical measurements - Clinical Recovery Scale for COVID-19 Assessment

Time to clinical recovery in COVID-19 Clinical Symptom Scale: The clinical symptom scale has been designed for this study to access the clinical state and time taken to relieve the clinical symptoms of COVID-19 (fever, dry cough, tiredness, aches and pains, sore throat, diarrhea, headache, loss of taste, loss of smell, difficulty in breathing or shortness of breath and chest pain or pressure).

Time frame: Every day from screening till discharge and Day 14 after last IP administration

Clinical measurements Clinical Improvement Scale for COVID-19 Assessment

Proportion of Clinical Improvement in Clinical Symptom Scale (Count of subjects with and without a symptom by treatment group on each day with the previous day counts during the study period).

Time frame: Daily from screening to discharge or Day 14 after last IP administration

Assessment of Quality of life - WHO-5 Well-Being Index

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Safety and tolerability assessment after administration of TADIOS 1

Subject incidence of Treatment-Emergent Adverse Events (TEAEs) and total number of unique TEAEs.

Time frame: Screening, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration

Safety and tolerability assessment after administration of TADIOS - Hematology

Change from baseline in Hematology, Complete Blood Count results WBC, RBC, Hb, HCT, MCV, MCH, MCHC, PLT, MPV, differential count of WBC (Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil), and ESR.

Time frame: Screening, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration

Safety and tolerability assessment after administration of TADIOS - Serum Chemistry

Change from baseline in Serum Chemistry results: total protein, albumin, globulin, A/G ratio, total bilirubin, AST, ALT, GGT, Random glucose, BUN, creatinine, estimated GFR, Ca2+, phosphate, Na+, K+, Cl-, CRP, triglyceride, cholesterol, HDL-cholesterol, and LDL-cholesterol.

Time frame: Screening, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration

Safety and tolerability assessment after administration of TADIOS - Urinalysis

Change from baseline in Urinalysis results: Color, pH, Specific gravity, albumin, bilirubin, glucose, urobilinogen, ketone, nitrite, hematuria, leukocyte and microscopy.

Time frame: Screening, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration

Safety and tolerability assessment after administration of TADIOS - Blood Pressure

Change from baseline in Blood Pressure in mm Hg.

Time frame: Screening, Maximum Day 10 (The date of discharge or early termination, at Day 1, 2, 4, 7, 10) and Day 14 after last IP administration

Safety and tolerability assessment after administration of TADIOS - Body Temperature

Change from baseline in Body Temperature ℃.

Time frame: Screening, Maximum Day 10 (The date of discharge or early termination, at Day 1, 2, 4, 7, 10) and Day 14 after last IP administration

Safety and tolerability assessment after administration of TADIOS - Pulse Rate

Change from baseline in Pulse Rate in beats per minute.

Time frame: Screening, Maximum Day 10 (The date of discharge or early termination, at Day 1, 2, 4, 7, 10) and Day 14 after last IP administration

Safety and tolerability assessment after administration of TADIOS - Respiration Rate

Change from baseline in Respiration Rate in breaths per minute.

Time frame: Screening, Maximum Day 10 (The date of discharge or early termination, at Day 1, 2, 4, 7, 10) and Day 14 after last IP administration